| Active substance | updacitinib |
| Holder | AbbVie Belgium sa/nv |
| Status | Running |
| Indication | the treatment of patients with active Crohn's Disease who have no other suitable treatment option and are not eligible to participate in a clinical study for their serious condition |
| Public documents | Approbation |
| Information for the patient | |
| Informed consent | |
| Last update | 27/02/2023 |